Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type

The purpose of this study is to learn if aripiprazole is safe and effective in the treatment of psychosis associated with dementia of the Alzheimer's type.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Alabama
      • Tuscaloosa, Alabama, United States
        • Local Institution
    • Arizona
      • Scottsdale, Arizona, United States
        • Local Institution
    • California
      • Cerritos, California, United States
        • Local Institution
      • Granada Hills, California, United States
        • Local Institution
      • Los Angeles, California, United States
        • Local Institution
      • San Diego, California, United States
        • Local Institution
      • Torrance, California, United States
        • Local Institution
    • Colorado
      • Denver, Colorado, United States
        • Local Institution
    • Connecticut
      • Hamden, Connecticut, United States
        • Local Institution
    • Florida
      • Miami, Florida, United States
        • Local Institution
      • North Miami Beach, Florida, United States
        • Local Institution
      • West Palm Beach, Florida, United States
        • Local Institution
    • Georgia
      • Atlanta, Georgia, United States
        • Local Institution
      • Augusta, Georgia, United States
        • Local Institution
      • Macon, Georgia, United States
        • Local Institution
    • Hawaii
      • Honolulu, Hawaii, United States
        • Local Institution
    • Illinois
      • North Chicago, Illinois, United States
        • Local Institution
      • Springfield, Illinois, United States
        • Local Institution
    • Louisiana
      • New Orleans, Louisiana, United States
        • Local Institution
      • Shreveport, Louisiana, United States
        • Local Institution
    • Maryland
      • Baltimore, Maryland, United States
        • Local Institution
    • Massachusetts
      • Newton Center, Massachusetts, United States
        • Local Institution
      • Springfield, Massachusetts, United States
        • Local Institution
      • Wellesley Hills, Massachusetts, United States
        • Local Institution
    • New Jersey
      • Lyons, New Jersey, United States
        • Local Institution
    • New York
      • Albany, New York, United States
        • Local Institution
      • Lawrence, New York, United States
        • Local Institution
      • Montrose, New York, United States
        • Local Institution
      • Northport, New York, United States
        • Local Institution
      • White Plains, New York, United States
        • Local Institution
    • North Carolina
      • Raleigh, North Carolina, United States
        • Local Institution
    • Ohio
      • Beachwood, Ohio, United States
        • Local Institution
    • Oregon
      • Portland, Oregon, United States
        • Local Institution
    • Pennsylvania
      • Hershey, Pennsylvania, United States
        • Local Institution
    • Texas
      • Austin, Texas, United States
        • Local Institution
      • Dallas, Texas, United States
        • Local Institution
      • San Antonio, Texas, United States
        • Local Institution
      • Wichita Falls, Texas, United States
        • Local Institution
    • Vermont
      • Bennington, Vermont, United States
        • Local Institution
    • Virginia
      • Charlottesville, Virginia, United States
        • Local Institution
    • Washington
      • Seattle, Washington, United States
        • Local Institution

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

55 years to 95 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Institutionalized patients with Alzheimer's

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2000

Primary Completion (Actual)

August 1, 2003

Study Completion (Actual)

August 1, 2003

Study Registration Dates

First Submitted

May 7, 2002

First Submitted That Met QC Criteria

May 8, 2002

First Posted (Estimate)

May 9, 2002

Study Record Updates

Last Update Posted (Estimate)

November 11, 2013

Last Update Submitted That Met QC Criteria

November 7, 2013

Last Verified

April 1, 2011

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Alzheimer Disease

Clinical Trials on aripiprazole

3
Subscribe